Effect of ocrelizumab on B-and T-cell receptor repertoire diversity in patients with relapsing multiple sclerosis from the randomized phase III OPERA Trial
Background and Objectives The B cell–depleting anti-CD20 antibody ocrelizumab (OCR)
effectively reduces MS disease activity and slows disability progression. Given the role of B …
effectively reduces MS disease activity and slows disability progression. Given the role of B …
Immune profiling reveals the T-cell effect of ocrelizumab in early relapsing-remitting multiple sclerosis
A Garcia, E Dugast, S Shah, J Morille… - Neurology …, 2023 - AAN Enterprises
Background and Objectives Ocrelizumab (OCR), a humanized anti-CD20 monoclonal
antibody, is highly efficient in patients with relapsing-remitting multiple sclerosis (RR-MS) …
antibody, is highly efficient in patients with relapsing-remitting multiple sclerosis (RR-MS) …
[HTML][HTML] Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab
B cell depletion by the anti-CD20 antibody ocrelizumab is effective in relapsing-remitting
(RR) and primary progressive (PP) multiple sclerosis (MS). We investigated immunological …
(RR) and primary progressive (PP) multiple sclerosis (MS). We investigated immunological …
Efficacy of Ocrelizumab in Patients with Relapsing Multiple Sclerosis: Pooled Analysis of Two Identical Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a …
Objective To evaluate the efficacy of ocrelizumab compared with interferon beta-1a (IFNβ-
1a) through pooled analysis of efficacy in OPERA I and OPERA II. Background MS …
1a) through pooled analysis of efficacy in OPERA I and OPERA II. Background MS …
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
Objective The efficacy and safety of ocrelizumab, versus interferon (IFN) β-1a, for the
treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I …
treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I …
Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8+ T-Cell Proliferation in Patients With Multiple Sclerosis
G Abbadessa, MT Lepore, S Bruzzaniti… - Neurology …, 2024 - AAN Enterprises
Background and Objectives The role of B cells in the pathogenic events leading to relapsing
multiple sclerosis (R-MS) has only been recently elucidated. A pivotal step in defining this …
multiple sclerosis (R-MS) has only been recently elucidated. A pivotal step in defining this …
[HTML][HTML] Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis
A Mathias, V Pantazou, S Perriot… - Neurology …, 2023 - AAN Enterprises
Background and Objective Depleting CD20+ B cells is the primary mechanism by which
ocrelizumab (OCRE) is efficient in persons with multiple sclerosis (pwMS). However, the …
ocrelizumab (OCRE) is efficient in persons with multiple sclerosis (pwMS). However, the …
Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis
Background and Objectives Ocrelizumab improved clinical and MRI measures of disease
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
N Capasso, R Palladino, V Cerbone, AL Spiezia… - Journal of …, 2023 - Springer
Objective We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …